Celltrion's blood cancer drug 'Truxima' receives interchangeability status in the US
⚡ Quick Summary
(Seoul = Yonhap News) Reporter Park Sang-hyun = Celltrion [068270] received a trademark approval from the U.S.
(Seoul = Yonhap News) Reporter Park Sang-hyun = Celltrion [068270] received a trademark approval from the U.S. Food and Drug Administration (FDA) for its blood cancer treatment drug 'Truxima' (ingredient name: rituximab)...
← Back